Biologic discontinuation studies: a systematic review of methods

• Published in: Annals of the rheumatic diseases Vol. 73; no. 3; pp. 595 - 599
• Main Authors: Yoshida, Kazuki, Sung, Yoon-Kyoung, Kavanaugh, Arthur, Bae, Sang-Cheol, Weinblatt, Michael E, Kishimoto, Mitsumasa, Matsui, Kazuo, Tohma, Shigeto, Solomon, Daniel H
• Format: Journal Article
• Language: English
• Published: United States Elsevier Limited 01.03.2014
• Subjects: Antirheumatic Agents - administration & dosage; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Biological Products - administration & dosage; Biological Products - therapeutic use; Clinical medicine; Disease control; Drug Administration Schedule; Humans; Remission Induction - methods; Research Design; Rheumatoid arthritis; Studies; Terminology as Topic; Treatment Failure; Tumor necrosis factor-TNF; Withholding Treatment; biologic DMARDs; rheumatoid arthritis; discontinuation; remission
• ISSN: 0003-4967; 1468-2060; 1468-2060
• DOI: 10.1136/annrheumdis-2013-203302

Objectives We conducted a systematic review to assess the design and ‘failure definition’ in studies of biologic discontinuation in rheumatoid arthritis (RA). Methods We found 403 studies on PubMed, and included nine published papers and five abstracts from scientific meetings. We used a structured extraction form to collect information regarding study design and outcome (failure) definition. Results Three types of studies were found: randomised controlled trials, long-term extension studies of clinical trials and prospective discontinuation studies. The largest study had 196 subjects in the discontinuation arm. Most studies allowed concomitant use of non-biologic drugs at biologic discontinuation. Heterogeneity was also found in the failure definition. Although all studies used measures of disease activity, the threshold for failure and the time point of assessment differed among studies. Few studies incorporated changing use of non-biologic drugs or glucocorticoids into the failure definition. Conclusions Although many studies have examined the outcome of biologic discontinuation, they have all been relatively small. Typical practice studies from registries may add important information but will likely need to rely on a broader failure definition.